Intrinsiqq
Decoy Therapeutics Inc. logo

Decoy Therapeutics Inc. Financials

DCOY

Compare

All currency values in $ millions unless otherwise noted

Scroll

Showing 6 of 13 available years
Income Statement
TTM
~8.7:1 split
DEC 2025
18:1 split
DEC 2024
~2.4:1 split
DEC 2023
~1.5:1 split
DEC 2022
DEC 2021
~2.7:1 split
Revenues
Revenue$1–––$0$2
General & Administrative$5$4$5$6$7$6
Research & Development$3$9$0$7$16$9
Total Operating Expenses$8$13$6$13$32$15
Operating Income-$8-$13-$6-$13-$32-$13
Income Tax Expense–$0––––
Net Income
Net Income-$7-$13-$6-$13-$32-$13
Per Share Data
Revenue Per Share$0.63–––$0.00$1,601.50
EPS (Basic)-$110.96-$129.10-$69.54-$5,533.20-$21,427.20-$11,116.80
EPS (Diluted)-$110.96-$129.10-$69.54-$5,533.20-$21,427.20-$11,116.80
Weighted Avg Shares (Basic)845,43996,967962,2103.3M2.1M41.4M
Weighted Avg Shares (Diluted)845,43996,967962,2103.3M2.1M41.4M
Shares Outstanding845,43996,9675,345.6112,267.0971,475.3551,149.054

Decoy Therapeutics (DCOY) financials: revenue, profit and margins

Decoy Therapeutics (DCOY) generated about n/a in revenue and -$17 million in net income over the trailing twelve months, growing at roughly 12.7% a year. Figures are from SEC filings; this is analysis, not investment advice.

Frequently asked

Is Decoy Therapeutics profitable?+

Decoy Therapeutics reported about -$17 million in net loss over the trailing twelve months. Net income is the bottom line after all costs, interest and taxes. Compare it to free cash flow on this tab, since reported profit and actual cash generated can diverge.

How fast is Decoy Therapeutics growing?+

Decoy Therapeutics's revenue has compounded at roughly 12.7% a year over the past five years. Growth only creates value when it is profitable and cash-generative, so read this rate alongside DCOY's margins and free cash flow. This is analysis from SEC filings, not investment advice.

How the market compares: How many US companies are profitable

SourceFinancial statements computed from the 10-Q filed 11 Nov 2026, covering the period ending 30 Sept 2026, as reported to the SEC. Data last refreshed 13 Nov 2026. How this is calculated.

Fiscal year ends Dec.

Peers

Pharmaceutical Preparations · Pick stocks to compare with DCOY

CompareIntrinsic value
SCPXScorpius Holdings Inc.
$0.00+0.00%10
CPMDCannapharmaRx Inc.
$0.00+0.00%24
SGMTSagimet Biosciences Inc.
$9.12-5.20%10
ORMPOramed Pharmaceuticals Inc.
$3.57-3.25%35
DNTHDianthus Therapeutics Inc.
$84.55-0.33%10
CYCNCyclerion Therapeutics Inc.
$35.45+6.55%40
PLRXPliant Therapeutics Inc.
$0.60-4.02%10
MCRBSeres Therapeutics, Inc.
$1.24-6.77%0

Held by ETFs

DCOY is in 1 US ETF. The largest of them, with DCOY's weight in each:

Spot a number that looks wrong? Check it in DCOY's SEC filings or

Download this analysis as a PDF (Pro)

Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.

5 of 5 free stocks used today

Keep analysing DCOY

A free account gives you 10 stocks a day, a watchlist and price alerts.

Already have an account?

Or come back tomorrow. Stocks on your watchlist are always free to view.

MarketsPrivacyTerms© 2026 Intrinsiqq

Not financial advice. Analytical data for research only.

Intrinsiqq is a Netherlands-based company operating in Rotterdam, KvK 73238007.